Boule Diagnostics AB (publ) (STO:BOUL)
Sweden · Delayed Price · Currency is SEK | Market Cap | 134.75M -57.1% |
| Revenue (ttm) | 478.39M -8.6% |
| Net Income | -8.05M |
| EPS | -0.21 |
| Shares Out | 38.83M |
| PE Ratio | n/a |
| Forward PE | 150.71 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 14,888 |
| Open | 3.480 |
| Previous Close | 3.300 |
| Day's Range | 3.340 - 3.550 |
| 52-Week Range | 3.090 - 10.600 |
| Beta | 0.18 |
| Analysts | Hold |
| Price Target | 3.80 (0.0%) |
| Earnings Date | Jul 17, 2026 |
About Boule Diagnostics AB
Boule Diagnostics AB (publ) develops, manufactures, and markets instruments and consumable products for blood diagnostics in the United States of America, Asia, Eastern Europe, Latin America, Western Europe, Africa, and the Middle East. It operates through Diagnostics and OEM Clinical Diagnostic Solutions. The company provides hematology analyzers, reagents, controls, and calibrators, under the Swelab, and Medonic brands; and veterinary hematology and clinical chemistry analyzer systems, as well as reagents and panels under the Exigo brand. It ... [Read more]
Financial Performance
In 2025, Boule Diagnostics AB's revenue was 489.69 million, a decrease of -12.31% compared to the previous year's 558.46 million. Losses were -3.75 million, -98.73% less than in 2024.
Financial StatementsNews
Boule Diagnostics AB Earnings Call Transcript: Q1 2026
Q1 2026 saw a return to organic growth and strong operating cash flow, despite a 10% sales decline due to currency headwinds and one-off costs from site consolidation. Margin pressures are seen as temporary, with strategic initiatives underway to drive future profitability.
Boule Diagnostics AB Quarterly report: Q1 2026
Boule Diagnostics AB has published its Q1 2026 quarterly earnings report on April 28, 2026.
Boule Diagnostics AB Slides: Q1 2026
Boule Diagnostics AB has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 28, 2026.
Boule Diagnostics AB Earnings Call Transcript: Q4 2025
Q4 saw sales decline due to currency headwinds and the India transition, but gross margin and cash flow improved. Structural cost reductions and operational efficiencies were achieved, with new product launches and OEM growth expected in coming years.
Boule Diagnostics AB Annual report: Q4 2025
Boule Diagnostics AB has published its Q4 2025 annual report on February 11, 2026.
Boule Diagnostics AB Quarterly report: Q4 2025
Boule Diagnostics AB has published its Q4 2025 quarterly earnings report on February 11, 2026.
Boule Diagnostics AB Slides: Q4 2025
Boule Diagnostics AB has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 11, 2026.
Boule Diagnostics AB Earnings Call Transcript: Q3 2025
Organic growth returned in Q3 with strong instrument sales and improved margins, despite currency headwinds and lower gross profit. Strategic cost reductions and new product agreements support a positive outlook, with continued focus on margin expansion and cash flow.
Boule Diagnostics AB Quarterly report: Q3 2025
Boule Diagnostics AB has published its Q3 2025 quarterly earnings report on October 24, 2025.
Boule Diagnostics AB Slides: Q3 2025
Boule Diagnostics AB has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on October 24, 2025.
Boule Diagnostics AB Earnings Call Transcript: Q2 2025
Q2 saw a 3.3% organic sales decline, but instrument unit sales rose 17% year-over-year, with 5-Part instrument sales more than doubling at lower prices. Operating expenses dropped 47%, and positive operating cash flow was achieved, despite margin pressures from currency and costs.
Boule Diagnostics AB Quarterly report: Q2 2025
Boule Diagnostics AB has published its Q2 2025 quarterly earnings report on July 18, 2025.
Boule Diagnostics AB Slides: Q2 2025
Boule Diagnostics AB has posted slides in relation to its Q2 2025 quarterly earnings report, which was published on July 18, 2025.